First Wave to merge with Im­muno­genX; Cali­way rais­es $100M; New deals for Re­play’s Sye­na

First Wave Bio­Phar­ma’s merg­er plans: The Flori­da biotech said it plans to merge with Im­muno­genX, an­oth­er gas­troin­testi­nal dis­eases com­pa­ny that is de­vel­op­ing an oral can­di­date known as latiglute­nase for celi­ac dis­ease. Af­ter the deal clos­es, First Wave said it ex­pects to an­nounce that a glob­al drug­mak­er is pay­ing for the com­mer­cial rights to the drug can­di­date as well as new fi­nanc­ing from undis­closed in­sti­tu­tion­al in­vestors. The Phase III tri­als are ex­pect­ed to be­gin in the sec­ond half of next year. — Kyle LaHu­cik

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.